Logo

ENGN

enGene Holdings Inc.

ENGN

enGene Holdings Inc. • NASDAQ
$8.07 ▼ -2.18% (-0.18)
Market Cap $413.14 M
52w High $11.14
52w Low $2.65
Dividend Yield 0%
P/E -4.25
Volume 332.72K
Outstanding Shares 51.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $29.947M ▲ $-28.991M ▼ 0% $-0.57 ▼ $-27.864M ▼
Q2-2025 $0 $27.124M ▲ $25.815M ▲ 0% $0.51 ▲ $-24.735M ▼
Q1-2025 $0 ▼ $26.613M ▲ $-24.616M ▼ 0% ▲ $-0.48 ▼ $-23.744M ▼
Q4-2024 $480K ▲ $17.455M ▲ $-15.299M ▼ -3.187K% ▼ $-0.34 ▼ $-14.441M ▼
Q3-2024 $0 $16.759M $-14.148M 0% $-0.32 $-13.344M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $201.913M ▼ $245.55M ▼ $44.878M ▲ $200.672M ▼
Q2-2025 $217.392M ▲ $266.651M ▼ $39.36M ▲ $227.291M ▼
Q1-2025 $213.813M ▼ $285.932M ▼ $35.982M ▼ $249.95M ▼
Q4-2024 $238.332M ▼ $311.173M ▲ $38.561M ▲ $272.612M ▲
Q3-2024 $257.678M $266.879M $36.55M $230.329M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-28.991M ▼ $-25.634M ▼ $1.379M ▼ $-667K ▼ $-24.922M ▼ $-26.338M ▼
Q2-2025 $-25.815M ▼ $-22.947M ▲ $17.947M ▲ $199K ▲ $-4.801M ▲ $-22.992M ▲
Q1-2025 $-24.616M ▼ $-25.696M ▼ $-84.964M ▲ $1K ▼ $-110.658M ▼ $-25.995M ▼
Q4-2024 $-15.299M ▼ $-19.568M ▼ $-125.266M ▼ $60.16M ▲ $-84.674M ▼ $-19.806M ▼
Q3-2024 $-14.148M $-7.181M $-2K $51K $-7.132M $-7.183M

Five-Year Company Overview

Income Statement

Income Statement ENGN is a classic early‑stage biotech story: essentially no product revenue yet and ongoing losses driven by research and development and corporate costs. Losses have been meaningful but, in recent periods, the company appears to be tightening its spending relative to its capital base, with operating performance showing some early signs of improvement. Still, the business is entirely dependent on future clinical and regulatory success to ever generate meaningful sales, so today’s income statement mostly reflects investment in science rather than a commercial operation.

Balance Sheet

Balance Sheet The balance sheet shows a small but strengthened company. Cash and total assets have risen notably in the most recent period, suggesting successful fundraising or deal activity. Equity has moved from a weak or even negative position in earlier years to a more solid positive base, which improves financial resilience. Debt exists but remains modest compared with total capital, so the company does not appear heavily leveraged. Overall, ENGN now has a cleaner, better‑funded balance sheet than a few years ago, but still one that depends on continued access to capital over time.

Cash Flow

Cash Flow ENGN consistently uses cash rather than generates it, which is expected for a clinical‑stage biotech with no product revenue. Operating cash outflows have been steady but not extreme, indicating a controlled burn rate, and there is essentially no spending on heavy equipment or facilities. Free cash flow is negative, so the company must rely on raising funds from investors or partners. The key question going forward is how long the current cash can support clinical programs before additional financing is needed, especially as pivotal trials and regulatory work typically increase spending.

Competitive Edge

Competitive Edge ENGN’s competitive position rests on its proprietary non‑viral gene delivery platform and its focus on localized treatments, starting with bladder cancer. The DDX platform targets tissues directly rather than using viral vectors, which may offer safety, dosing, and convenience advantages. The lead program, EG‑70, addresses a form of bladder cancer with high unmet need, where patients and physicians are actively seeking alternatives to surgery or repeat procedures. Regulatory designations like Fast Track and RMAT add to its potential edge. However, the company remains small, focused on a narrow set of indications, and operates in a crowded oncology and gene‑therapy landscape where larger players and other novel modalities are also competing for similar patients.

Innovation and R&D

Innovation and R&D Innovation is ENGN’s core strength. The DDX platform enables non‑viral, localized gene delivery and appears flexible enough to carry different genetic payloads, including combinations that stimulate both innate and adaptive immunity. EG‑70 is a first‑in‑class program with encouraging clinical data and a mechanism designed specifically for bladder administration, which plays to the platform’s strengths. The company is exploring broader use of the technology in other organs such as the lungs and digestive system, suggesting a pipeline‑building opportunity beyond the lead indication. At the same time, this innovation strategy requires sustained R&D investment and careful clinical execution; setbacks in the pivotal bladder cancer program could slow or reshape the entire platform story.

Summary

ENGN is a small, clinical‑stage biotech with no current product revenue but a clearly differentiated non‑viral gene‑therapy platform. Financially, it has transitioned from a weaker balance sheet to a more solid capital foundation, though it still consumes cash and depends on external funding. The company’s value is concentrated in a single lead asset, EG‑70, and the underlying DDX platform, both of which target a high‑need area in bladder cancer with supportive early data and favorable regulatory designations. The upside lies in successful approval of EG‑70 and expansion of the platform into additional diseases; the main risks are clinical, regulatory, and financing‑related, as well as competition from other oncology and gene‑therapy approaches. Overall, ENGN is best understood as a focused, high‑risk, research‑driven story rather than a traditional operating business at this stage.

NEWS

November 25, 2025 · 7:30 AM UTC

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

Read more

November 13, 2025 · 12:27 AM UTC

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

Read more

November 12, 2025 · 4:01 PM UTC

enGene Announces Proposed Public Offering of Common Shares

Read more

November 11, 2025 · 7:30 AM UTC

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Read more

November 10, 2025 · 4:05 PM UTC

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

Read more